GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (HAM:MAH0) » Definitions » ROIC %

Mereo BioPharma Group (HAM:MAH0) ROIC % : -563.71% (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Mereo BioPharma Group ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Mereo BioPharma Group's annualized return on invested capital (ROIC %) for the quarter that ended in Jun. 2024 was -563.71%.

As of today (2024-09-25), Mereo BioPharma Group's WACC % is -8.72%. Mereo BioPharma Group's ROIC % is -124.28% (calculated using TTM income statement data). Mereo BioPharma Group earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Mereo BioPharma Group ROIC % Historical Data

The historical data trend for Mereo BioPharma Group's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group ROIC % Chart

Mereo BioPharma Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only -59.71 -65.57 -58.52 -174.05 -207.84

Mereo BioPharma Group Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -223.46 -1.62 - -529.85 -563.71

Competitive Comparison of Mereo BioPharma Group's ROIC %

For the Biotechnology subindustry, Mereo BioPharma Group's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mereo BioPharma Group's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's ROIC % distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's ROIC % falls into.



Mereo BioPharma Group ROIC % Calculation

Mereo BioPharma Group's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-24.884 * ( 1 - 1.77% )/( (18.242 + 5.279)/ 2 )
=-24.4435532/11.7605
=-207.84 %

where

Mereo BioPharma Group's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Jun. 2024 is calculated as:

ROIC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-46.244 * ( 1 - 0% )/( (7.81 + 8.597)/ 2 )
=-46.244/8.2035
=-563.71 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mereo BioPharma Group  (HAM:MAH0) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Mereo BioPharma Group's WACC % is -8.72%. Mereo BioPharma Group's ROIC % is -124.28% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Mereo BioPharma Group ROIC % Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mereo BioPharma Group Business Description

Comparable Companies
Traded in Other Exchanges
Address
One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.

Mereo BioPharma Group Headlines

No Headlines